Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An update from Biodexa Pharmaceuticals ( (BDRX) ) is now available.
On November 3, 2025, Biodexa Pharmaceuticals announced the approval of their Clinical Trial Application by the European Medicines Agency for the Phase 3 Serenta clinical trial of eRapa in patients with familial adenomatous polyposis (FAP). This approval allows the trial to proceed in several European countries, marking a significant step in potentially addressing a $7 billion market for FAP treatment. The trial aims to provide an alternative to the current standard of care, which involves invasive surgeries, by offering a pharmaceutical solution that could improve the quality of life for FAP patients.
The most recent analyst rating on (BDRX) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Biodexa Pharmaceuticals stock, see the BDRX Stock Forecast page.
Spark’s Take on BDRX Stock
According to Spark, TipRanks’ AI Analyst, BDRX is a Neutral.
Biodexa Pharmaceuticals has a low overall stock score of 45, driven by significant financial challenges, bearish technical indicators, and a poor valuation. The lack of positive earnings guidance further adds to the uncertainty. The company must improve financial performance and operational efficiency to enhance investor confidence.
To see Spark’s full report on BDRX stock, click here.
More about Biodexa Pharmaceuticals
Biodexa Pharmaceuticals PLC is a clinical stage biopharmaceutical company focused on developing innovative treatments for diseases with unmet medical needs. Their lead programs include eRapa for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer, tolimidone for type 1 diabetes, and MTX110 for aggressive rare/orphan brain cancers. The company leverages proprietary drug delivery technologies to improve the bio-delivery and bio-distribution of medicines.
Average Trading Volume: 141,206
Technical Sentiment Signal: Sell
Current Market Cap: $3.92M
For a thorough assessment of BDRX stock, go to TipRanks’ Stock Analysis page.